Numis announced Hikma Pharmaceuticals PLC (LON:HIK), boosting its stock price target to 2,660.00GBX today
- Updated: September 18, 2016
Numis bumped the price target of Hikma Pharmaceuticals PLC (LON:HIK) to 2,660GBX, reporting a possible upside of 0.18%.
Previously on 7/26/2016, Jefferies released a statement for Hikma Pharmaceuticals PLC(LON:HIK) raised the target price from 2,800.00GBX to 2,990.00GBX that suggested an upside of 0.13%.
Yesterday Hikma Pharmaceuticals PLC (LON:HIK) traded 0.80% lower at 2,258.00GBX. The company’s 50-day average is 2,273.76GBX and its 200-day moving average is 2,221.42GBX. With the last close up 4.75% relative to the two hundred day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Trade volume was was down over the average, with 508,620 shares of HIK changing hands under the typical 581,547 shares..
Recent Performance Chart:
Hikma Pharmaceuticals PLC has a price-earnings of 26 with a one-year low of 1,575.00GBX and a one-year high of 2,703.00GBX and has a total market value of 0.0 GBX.
Also covering Hikma Pharmaceuticals PLC’s target price, a total of 9 brokers have released a research note on the company. The one year target price is 32.71GBX with four analysts rating the company a strong buy, six firms rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and lastly 0 analystsrating the company as sell.
About Hikma Pharmaceuticals PLC (LON:HIK)
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company’s segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1, 120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business’ products include Argatroban, Fentanyl, Glycopyrrolate, and Nicardipine and Phenylephrine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.